A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform skin rash.

TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry ...

Infliximab injectable solution is a prescription medication that’s used to treat arthritis, ulcerative colitis, and other inflammatory diseases. It’s available only as the brand-name drugs ...

Infliximab is a monoclonal antibody that is administered intravenously to treat patients with chronic inflammatory diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis ...

From 2020 to 2021, a total of 8,388 infliximab infusions were administered to the 863 patients in the study. Of these, 39 patients experienced 49 AEs.

The Food and Drug Administration (FDA) has approved Zymfentra ® (infliximab-dyyb) for the maintenance treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

Infliximab concentrations above 6.9 mg/L at 14 weeks after initiation of treatment predicted sustained remission between 26 and 52 weeks in children with inflammatory bowel disease, according to ...

The readministration of infliximab resulted in prompt improvement in the disease activity of the rheumatoid arthritis (), meeting the criteria of the American College of Rheumatology for remission ...

Here we describe a patient receiving infliximab who had reactivation of cerebral toxoplasmosis. The patient was a 36-year-old woman in whom rheumatoid arthritis was diagnosed in 2000.

To compare cyclophosphamide vs. infliximab (Remicade, Janssen) as first-line therapies in severe Behçet’s syndrome, Saadoun and colleagues conducted a phase 2, open-label, randomized controlled ...

TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry ...

A 17-year-old white male with a 9-year history of ileocolonic Crohn's disease developed a skin rash while receiving infliximab, a chimeric IgG1κ monoclonal antibody against tumor necrosis factor ...